Document:

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                                                  Exhibit 10.13

      THIS AGREEMENT made in duplicate as of this 14 day of June, 2004.

BETWEEN:

                                    MDS NORDION, a division of MDS (Canada) Inc.
                                    having a place of business at
                                    447 March Road
                                    Ottawa, Ontario, Canada K2K1X8

                                    ("Nordion")

AND:

                                        MOLECULAR INSIGHT PHARMACEUTICALS, INC.
                                        having a place of business at
                                        160 Second Street
                                        Cambridge Massachusetts, 02142 USA

                                        ("Molecular Insight Pharmaceuticals")

WHEREAS:

I.    Molecular Insight Pharmaceuticals is the owner or licensee of a certain
      compound known as BMIPP (as defined), a heart diagnostic imaging agent;

II.   Nordion has expertise in the development of pharmaceutical processes and
      radiolabelling of compounds;

III.  Molecular Insight Pharmaceuticals has developed techniques and
      demonstrated an ability to label Precursor with 1-123 to form BMIPP;

IV.   Molecular Insight Pharmaceuticals desires that Nordion undertake at its
      facility a development program based upon Molecular Insight
      Pharmaceutical's technique which will allow Molecular Insight
      Pharmaceuticals' Precursor to be labeled with 1-123 to form BMIPP;

V.    Molecular Insight Pharmaceuticals desires that Nordion establish a
      facility at its site in Vancouver, British Columbia, to produce and supply
      BMIPP for use in support of Molecular Insight Pharmaceuticals' Phase III
      Clinical Trials and in support of Molecular Insight Pharmaceuticals' drug
      submission to the FDA.

NOW THEREFORE in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
parties hereto agree as follows:

<PAGE>

                                       2

                             ARTICLE 1 - DEFINITIONS

For the purposes of this Agreement:

1.1   "Affiliate" shall mean an entity or person which controls, is controlled
      by or is under common control with either party. For purposes of this
      Section 1.1 control shall mean (a) in the case of corporate entities, the
      direct or indirect ownership of more than one-half of the stock or
      participating shares entitled to vote for the election of directors, and
      (b) in the case of a partnership, the power to direct the management and
      policies of such partnership.

1.2   "BMIPP" shall mean a pharmaceutical product containing 1-123 labeled
      Precursor in diagnostic dosage form for cardiac imaging.

1.3   "Background Technology" shall mean all Nordion proprietary technology
      existing prior to the Effective Date, including patents, copyright,
      know-how, techniques, methods, processes and trade secrets which Nordion
      owns or which is licensed to Nordion and, in each case, which is in
      existence in the form of a writing, prototype or can otherwise be
      demonstrated to be the property of Nordion prior to the Effective Date.

1.4   "Batch" shall mean a production batch of BMIPP manufactured under this
      Agreement.

1.5   "Clinical Trial Batch Size" shall have the meaning attributed in Section
      4.1.

1.6   "Clinical Trials" shall mean Phase III human trials for clinical
      development of BMIPP in the United States.

1.7   "Commercial Phase" shall mean the period of supply of BMIPP commencing
      after NDA regulatory approval has been received in the United States by
      Molecular Insight Pharmaceuticals, from the FDA.

1.8   "Current Good Manufacturing Practices" or "cGMP(s)" shall mean the good
      manufacturing practices required by the FDA and as set forth in the FD&C
      or FDA rules and regulations for the manufacturing, testing and quality
      control of pharmaceutical materials as applied to compounds, which
      practices are current on the Effective Date of this Agreement and may be
      supplemented, amended or modified from time to time.

1.9   "Development Phase" shall mean the period commencing from the Effective
      Date until completion of the activities described in Schedule A.

1.10  "Effective Date" shall mean the date first above written.
<PAGE>
                                        3

1.11  "FDA" shall mean the United States Food and Drug Administration.

1.12  "FD&C" shall mean the United States Federal Food, Drug and Cosmetic Act,
      as amended.

1.13  "Facility" shall mean the facility to be established by Nordion at its
      manufacturing site in Vancouver, British Columbia as described in Schedule
      B and pursuant to cGMPs, to be used for the production of BMIPP for
      diagnostic applications and purposes.

1.14  "IND" shall mean an Investigational New Drug Application as defined by the
      rules and regulations promulgated under the FD&C and U.S. Public Health
      Service Act and any supplements, modifications or amendments thereunder.

1.15  "Isotope" or "I-123" shall mean Iodine 123.

1.16  "Master Validation Plan" shall mean the program mutually agreed to by the
      parties by which documented evidence provides assurance that the Process
      will consistently produce BMIPP that meets Specifications.

1.17  "NDA" shall mean a new drug application as defined in the rules and
      regulations promulgated under the FD&C and U.S. Public Health Service Act,
      as supplemented, modified or amended from time to time.

1.18  "Precursor" shall mean (beta)-methyl-p-iodophenyl-pentadecanoic acid
      specified in Schedule C and produced pursuant to cGMPs.

1.19  "Process" shall mean the method of formulation, dispensing, and testing of
      the BMIPP developed under this Agreement and in compliance with cGMPS.

1.20  "Reference Standards" shall mean the cGMP compliant compounds as specified
      in Schedule D.

1.21  "Specification(s)" shall mean those final specifications for BMIPP as set
      out in Schedule E, as amended by mutual agreement of the parties from time
      to time.

                              ARTICLE 2 - PURPOSE

2.1   Scope and Object

      The scope and object of this Agreement is to carry out the development of
      the Process in accordance with the responsibilities and obligations
      attributed to each of the parties as set out in this Agreement. In
      addition,

<PAGE>

                                        4

      this Agreement shall provide for the establishment of a Facility to be
      utilized, amongst other purposes, in the production and supply of BMIPP as
      required in support of Molecular Insight Pharmaceuticals' BMIPP Phase III
      Clinical Trial and NDA submission to the FDA.

                         ARTICLE 3 - DEVELOPMENT PHASE

3.1   Development Activities

      During the Development Phase, Nordion and Molecular Insight
      Pharmaceuticals shall carry out their respective obligations described and
      attributed in Schedule A, it being understood that some activities may be
      reasonably delayed to the extent that such activity is premised on the
      work or provision of data, information or technology by the other party.
      It is understood and acknowledged that due to the developmental nature of
      the activities to be carried out during the Development Phase, the time
      for completion and sequence for carrying out the activities as set out in
      Schedule A shall serve as a guide. Each party shall use their commercially
      reasonable best efforts in order to carry out, in a timely manner, their
      respective obligations and responsibilities set out in Schedule A.

      If either party, acting in good faith, materially fails to satisfy any
      milestone or is unable to meet such milestone in accordance with the
      timing set out in Schedule A, such party shall provide written notice
      thereof to the other party and the parties shall determine a reasonable
      corrective action plan and revised milestone schedule. If the parties are
      unable to determine a reasonable corrective action plan and revised
      milestone schedule, the parties may submit such matter to binding
      arbitration in Vancouver, British Columbia, pursuant to and conducted
      under the International Commercial Arbitration Act of British Columbia,
      which arbitration shall be conducted before a single arbitrator possessing
      appropriate industry experience as selected by the parties. If the parties
      cannot agree on a single arbitrator, the arbitrator shall be appointed in
      accordance with the International Commercial Arbitration Act of British
      Columbia. The decision of the arbitrators shall be final and binding.

      The parties acknowledge and agree that Schedule A may be amended during
      the course of the Development Phase to accommodate unforeseen events and
      results. All such changes to Schedule A shall be made by written agreement
      of the parties. If any change to Schedule A materially impacts the scope
      of work to be provided by Nordion, Nordion will provide a written estimate
      of the increase in hours of work at the rates set forth in Section 6.3,
      which must be approved in advance by Molecular Insight Pharmaceuticals. No
      work on such scope change shall be carried out by

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       5

      Nordion prior to Nordion's receipt of Molecular Insight Pharmaceuticals'
      written approval of such change.

      The parties, upon signing this Agreement, shall each designate a program
      manager, who shall be responsible for coordinating communication and
      monitoring performance under this Agreement. The program managers shall
      meet monthly, in person or by telephone, for the purpose of reviewing the
      status of the project, assessing progress against the milestones and
      activities set forth in Schedule A, and determining the percentage of each
      milestone completed and the payments earned, if any, in connection with
      each milestone. Minutes of meetings shall be prepared, maintained and
      provided to each of the parties.

3.2   Development Phase Work

      In consideration of Nordion performing the Development Phase services,
      Molecular Insight Pharmaceuticals shall pay Nordion in accordance with the
      rates set out in Schedule F, which schedule includes amounts payable upon
      achievement of milestones as well as amounts payable for each Batch
      produced and supplied by Nordion hereunder. All amounts due Nordion shall
      be paid by Molecular Insight Pharmaceuticals within thirty (30) days of
      the date appearing on Nordion's invoice. Such invoice shall, unless
      otherwise agreed, be payable in United States dollars.

3.3   Facility Program

      In consideration of Nordion establishing the Facility, Molecular Insight
      Pharmaceuticals will pay to Nordion a non-reimbursable facility fee of
      [**********************] United States dollars (US $[********]) upon
      execution of this Agreement.

      After the Facility is completed, Nordion shall, in consultation with
      Molecular Insight Pharmaceuticals, develop and implement a Master
      Validation Plan for the Facility that will allow the production of BMIPP
      under cGMPs in the volumes required by Molecular Insight Pharmaceuticals
      for Phase III clinical supply as described in Section 4.1. The costs of
      preparation, development and implementation of the Master Validation Plan
      will be borne by Nordion. Prior to implementation, both parties shall in
      writing approve the Master Validation Plan. Nordion shall ensure that the
      Facility is available for the production of BMIPP for supply to Molecular
      Insight Pharmaceuticals on a priority basis at least three days per week
      to be mutually agreed between the parties.

3.4   Repairs and Maintenance

<PAGE>

                                        6

      After the Facility is established, Nordion shall maintain such Facility in
      satisfactory operating condition as required by the Specifications,
      Process and cGMPs, and all other applicable laws, regulations, rules or
      orders. The cost of repairs, preventive maintenance and service contracts
      for the Facility shall be borne by Nordion.

3.5   Commercial Phase Negotiations

      Within thirty (30) days after completion of Milestone 2 under the
      Development Phase, the parties shall for a period of at least sixty (60)
      days enter into good faith negotiations for the supply of BMIPP to
      Molecular Insight Pharmaceuticals, during the Commercial Phase.

              ARTICLE 4 - BATCH SIZE IN SUPPORT OF NDA SUBMISSION

4.1   Clinical Supply Batch Size

      The Batch size for Clinical Trial supply shall be thirty (30) doses of
      BMIPP. The maximum number of vials available for shipment from any Batch
      will be twenty (20) doses with the remainder being retained by Nordion for
      archival and quality assurance testing. BMIPP will be shipped in an
      appropriate lead shield, which will be provided at Nordion's expense. All
      necessary labels for shipment will be provided by Molecular Insight
      Pharmaceuticals and shall meet all applicable regulatory requirements.

                       ARTICLE 5 - GENERAL MANUFACTURE AND
                         SUPPLY OBLIGATIONS OF NORDION

5.1   BMIPP Supply

      Nordion agrees to (i) use the Process to produce Batches of BMIPP that
      meet the Specifications and are manufactured in conformance with cGMPs and
      (ii) ship BMIPP to customers as directed by Molecular Insight
      Pharmaceuticals. Nordion reserves the right to withhold from shipment any
      Batch which does not conform to Specifications. The price of any Batch
      required by Molecular Insight Pharmaceuticals during the term of this
      Agreement shall be as set out in Schedule F. The parties agree that
      Molecular Insight Pharmaceuticals will provide BMIPP at its expense and
      Nordion will supply isotopes and other supplies at its expense.

5.2   Compliance with Law; Handling of BMIPP

      While Precursor, Isotope and BMIPP are in its possession or under its
      control, Nordion shall be responsible for compliance with applicable
      statutory and regulatory requirements in the United States and Canada
      regarding the development, manufacture, handling, storage, labeling,

<PAGE>

                                        7

      packaging, transportation and shipment of the Precursor, Isotope and
      BMIPP.

5.3   Testing and Documentation

      Nordion shall maintain accurate and complete production records with
      respect to the Process, Batches and shipments and Molecular Insight
      Pharmaceuticals shall have access to such records in order to determine
      that each Batch was produced and tested in compliance with the
      Specifications and cGMP requirements.

      The tests and analyses provided in the Specifications as well as the
      nature and form of records may be amended by Nordion from time to time,
      subject to the consent of Molecular Insight Pharmaceuticals, which shall
      not be unreasonably withheld after Nordion shall have delivered to
      Molecular Insight Pharmaceuticals, in writing, an explanation of such
      changes and why they are necessary or advisable.

                               ARTICLE 6 - GENERAL
                  MOLECULAR INSIGHT PHARMACEUTICALS OBLIGATIONS

6.1   Precursor and Reference Standards

      Molecular Insight Pharmaceuticals or, at Molecular Insight
      Pharmaceuticals' discretion its designee, shall provide Precursor and
      Reference Standards to Nordion at no charge, which meets the
      specifications in Schedules C and D in sufficient quantities to permit
      Nordion to meet its obligations hereunder. Nordion shall only use
      Precursor and Reference Standards for the manufacture of BMIPP pursuant to
      this Agreement. Nordion shall store Precursor and Reference Standards in
      accordance with its applicable specifications set out in Schedule C and D
      respectively. Molecular Insight Pharmaceuticals shall at all times retain
      title in and to such materials in Nordion's possession.

6.2   Unavailability or Scarcity of Precursor or Reference Standards

      Molecular Insight Pharmaceuticals will notify Nordion upon Molecular
      Insight Pharmaceuticals becoming aware of a shortage of supply of
      Precursor or Reference Standards, if such shortage will impact the
      manufacture of the BMIPP. Except as set out below, Molecular Insight
      Pharmaceuticals shall not be liable for any delays or shortages in the
      supply of Precursor or Reference Standards, provided however, that any
      such shortages or delays in Precursor or Reference Standards supply will
      excuse Nordion's performance of activities related to such Batch of BMIPP
      only to the extent that Nordion's non-performance was caused by the

<PAGE>
                                       8

      Precursor or Reference Standards supply delay or shortage and only for a
      period of time equal to the delay.

6.3   Additional Compensation to Nordion

      In addition to the amounts set forth in Schedule F, Molecular Insight
      Pharmaceuticals will compensate Nordion based on the rate of one hundred
      and twenty-five United States dollars (US$125.00) per person per hour for
      the time spent by Nordion on the following activities only and upon
      Molecular Insight Pharmaceuticals prior written request:

      (i)   preparing and hosting Facility audits requested by Molecular Insight
            Pharmaceuticals including FDA preaudit inspections;

      (ii)  preparing responses to FDA inquiries and preparation by Nordion of
            information requested by Molecular Insight Pharmaceuticals in
            support of Molecular Insight Pharmaceuticals' BMIPP NDA submission;
            and

      (iii) attending meetings with the FDA.

      Molecular Insight Pharmaceuticals shall reimburse Nordion for all costs
      incurred for travel and accommodation in carrying out the foregoing
      activities. Nordion shall provide an estimate of all such activities to
      Molecular Insight Pharmaceuticals prior to incurring the expenditure.

                          ARTICLE 7 - BMIPP SHIPMENTS

7.1   Orders and Shipments

      During the term of this Agreement, Molecular Insight Pharmaceuticals will
      forward orders to Nordion at its Kanata, Ontario facility by facsimile.
      Each order will set forth the quantity to be produced and shipped, the
      identity of the recipient, delivery destination protocol number, IND
      number, applicable USNRC materials license number and IRS number. Delivery
      of BMIPP to Molecular Insight Pharmaceuticals or as otherwise directed by
      Molecular Insight Pharmaceuticals shall be FOB transport vehicle at
      Nordion's facility in Vancouver, British Columbia. Risk of loss of BMIPP
      shall pass to Molecular Insight Pharmaceuticals at point of delivery.

      During the term of this Agreement Nordion shall use commercially
      reasonable best efforts to meet Molecular Insight Pharmaceuticals' orders
      and delivery requirements. Prior to the first shipment of BMIPP to any
      third party site, Molecular Insight Pharmaceuticals shall obtain from such
      third party and provide to Nordion such third party's license evidencing
      proper legal authority for the receipt and possession of the BMIPP by such
      third party. Molecular Insight Pharmaceuticals shall obtain all approvals,
      licenses and permits required to import BMIPP into the United States.
<PAGE>

                                        9

      Nordion shall make shipping arrangements with AirNet Express or such other
      carrier designated by Nordion and reasonably approved by Molecular Insight
      Pharmaceuticals. All shipping costs incurred to deliver BMIPP shall be
      borne by Molecular Insight Pharmaceuticals.

      Molecular Insight Pharmaceuticals shall be entitled to cancel any Batch
      ordered from Nordion by providing to Nordion at least two (2) business
      days written notice of cancellation prior to the later of commencement of
      production or the scheduled production date. The failure to give notice
      hereunder shall result in Molecular Insight Pharmaceuticals being required
      to pay the full purchase price of such Batch to Nordion. All orders for
      BMIPP shall be forwarded by Molecular Insight Pharmaceuticals and received
      by Nordion by the Friday Noon (Eastern time) prior to the week in which
      BMIPP is to be manufactured.

7.2   Warranty/Recall

      Nordion warrants the BMIPP will meet the Specifications and be
      manufactured in accordance with cGMP's and be free from defects in
      material and workmanship for the period from the date of manufacture to
      the expiry date set out on each vial of BMIPP.

      If either party discovers that a Batch of BMIPP does not meet the
      Specifications, then the discovering party shall promptly communicate with
      the other party. If Molecular Insight Pharmaceuticals determines that the
      failure to meet Specifications results from an act, failure to act or
      other fault of Nordion, or agent of Nordion, Nordion will promptly:

      (i) repair or replace such batch of BMIPP; and

      (ii) pay for shipping costs of replacement of BMIPP.

      In the event that Nordion disputes Molecular Insight Pharmaceuticals'
      determination that the fault id due to Nordion and/or its agent, the
      parties will select a mutually acceptable outside consulting firm which
      will be instructed to review the applicable information and data and
      confirm or dissent from Molecular Insight Pharmaceuticals' determination.
      If the consulting firm confirms Molecular Insight Pharmaceuticals'
      determination, Nordion will have the obligations set out in this Section
      and Nordion will pay the fees of such consulting firm. If the consulting
      firm dissents from Molecular Insight Pharmaceuticals' determination or
      determines that the failure to meet Specifications was due to products,
      information or services supplied by Molecular Insight Pharmaceuticals,
      Nordion will not have the obligations set out in this Section with respect
      to the disputed Batch and Molecular Insight Pharmaceuticals will pay the
      fees for such consulting firm.

<PAGE>

                                       10

                               ARTICLE 8 - LICENSE

8.1   Royalty-Free License

      Molecular Insight Pharmaceuticals hereby provides to Nordion a
      nonexclusive, nontransferable, royalty-free license during the term of
      this Agreement to use the patents, data, information and technology
      provided by Molecular Insight Pharmaceuticals relating to BMIPP and the
      radiolabelling of 1-123 with Precursor for the sole purpose of assisting
      Nordion in carrying out its obligations set out in this Agreement.
      Molecular Insight Pharmaceuticals represents and warrants that the
      technology provided by Molecular Insight Pharmaceuticals relating to BMIPP
      allows for BMIPP to be terminally sterilized while still meeting the
      specifications set out in Schedule E.

                  ARTICLE 9 - MOLECULAR INSIGHT PHARMACEUTICALS
                         REPRESENTATIONS AND WARRANTIES

9.1   Molecular Insight Pharmaceuticals' Representations and Warranties

      Molecular Insight Pharmaceuticals represents, warrants and covenants that:

      (i)   it has full right, power and authority to enter into this Agreement;

      (ii)  it is the owner or has the right of use of the patents, data,
            information and technology supplied to Nordion by Molecular Insight
            Pharmaceuticals to assist Nordion in manufacturing BMIPP and in
            carrying out its obligations hereunder;

      (iii) to Molecular Insight Pharmaceuticals' knowledge, there is no action
            or proceeding pending or threatened against Molecular Insight
            Pharmaceuticals before any court, administrative agency or other
            tribunal which might have an adverse material effect on its ability
            to perform its obligations hereunder;

      (iv)  it has the right to grant the license in section 8.1 and right to
            permit Nordion to use the patents, technology and know how provided
            to the extent required to assist Nordion in carrying out its
            obligations under this Agreement;

      (v)   it has not received any notice of adverse claim or infringement of
            any patent, copyright, or misappropriation of trade secrets in
            connection with the use and exploitation of the Precursor, Reference
            Standard or BMIPP;

      (vi)  to Molecular Insight Pharmaceuticals' best information and belief,
            use or sale of Precursor, Reference Standards and BMIPP and the
            data, information, technology and know how used in the Process and
            manufacture of BMIPP contributed by Molecular Insight
            Pharmaceuticals do not infringe any valid third party patent,

<PAGE>

                                       11

            pending published patent application or other intellectual property
            right.

              ARTICLE 10 - NORDION'S REPRESENTATIONS AND WARRANTIES

10.1  Representations and Warranties

      Nordion represents, warrants and covenants that:

      (i)   it has full right and authority to enter into this Agreement;

      (ii)  it is the owner or has the right to use the data, information and
            technology contributed by it with respect to the Background
            Technology and other proprietary technology contributed by Nordion
            during the Agreement;

      (iii) the Background Technology contributed by Nordion does not, to
            Nordion's best information and belief, infringe any patents,
            copyright or other industrial or intellectual property rights of
            third parties;

      (iv)  it has not received any notice of adverse claim of infringement of
            any patent or misappropriation of trade secrets in connection with
            the use and exploitation of the data, information and technology
            used with respect to Background Technology contributed by Nordion;
            and

      (v)   to Nordiont's knowledge, there is no action or proceeding pending or
            threatened against Nordion before any court, administrative agency
            or other tribunal which might have a adverse material effect on
            Nordion's ability to perform its obligations hereunder.

                             ARTICLE 11 - INDEMNITY

11.1  Indemnification by Molecular Insight Pharmaceuticals

      Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
      Nordion and its Affiliates and their respective directors, officers,
      employees and agents, harmless from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorney's fees) resulting from any third party claims or suits ("General
      Claims Against Nordion") arising out of (a) Molecular Insight
      Pharmaceuticals' or a third party's use, handling or shipment of Reference
      Standards, Precursor or BMIPP, (b) Molecular Insight Pharmaceuticals'
      breach of any of its obligations, warranties or representations hereunder,
      or (c) Molecular Insight Pharmaceuticals' negligent acts or omissions or
      willful misconduct. Notwithstanding the foregoing, Molecular Insight
      Pharmaceuticals will not be required to indemnify, defend and hold Nordion
      and its Affiliates and their respective directors, officers, employees and
      agents harmless from and against any General Claims Against Nordion to the
      extent that such claims arise out of (i) Nordion's

<PAGE>

                                       12

      breach of any of its obligations, warranties or representations hereunder;
      (ii) Nordion's negligent acts or omissions or willful misconduct; (iii)
      any failure of Nordion to manufacture, handle, store, label, package,
      transport or ship BMIPP in accordance with this Agreement, cGMPs or any
      other applicable laws, rules, regulations or other requirements of any
      applicable governmental entity; or (iv) any failure of Nordion to
      manufacture BMIPP consistent with the Specifications and requirements set
      forth herein or with the applicable sections of Molecular Insight
      Pharmaceuticals' IND in the United States. Notwithstanding anything in
      this Section 11.1, "General Claims Against Nordion" shall not include "IP
      Claims Against Nordion" as described in Section 11.3.

11.2  Indemnification by Nordion

      Nordion agrees to indemnify, defend and hold Molecular Insight
      Pharmaceuticals and its Affiliates and their respective directors,
      officers, employees and agents, harmless from and against any damages,
      claims, liabilities and expenses (including, but not limited to,
      reasonable attorney's fees) resulting from any third party claims or suits
      ("General Claims Against Molecular Insight Pharmaceuticals") arising out
      of (a) Nordion's manufacture, handling, storage, labeling, packaging or
      delivery of the BMIPP; (b) Nordion's breach of any of its obligations,
      warranties or representations hereunder; (c) Nordion's negligent acts or
      omissions or willful misconduct; (d) any failure of the BMIPP to meet the
      Specifications; or (e) any failure of Nordion to manufacture, handle,
      store, label, package, transport or ship BMIPP in accordance with this
      Agreement or cGMPs or any other applicable laws, regulations or other
      requirements of any applicable governmental entity. Notwithstanding the
      foregoing, Nordion will not be required to indemnify, defend and hold
      Molecular Insight Pharmaceuticals and its Affiliates and their respective
      directors, officers, employees and agents harmless from and against any
      General Claims Against Molecular Insight Pharmaceuticals to the extent
      that such claims arise out of (i) Molecular Insight Pharmaceuticals'
      breach of any of its obligations, warranties or representations hereunder;
      (ii) Molecular Insight Pharmaceuticals' negligent acts or omissions or
      willful misconduct; (iii) any defect or failure of Reference Standards or
      Precursor to meet applicable specifications or (iv) Molecular Insight
      Pharmaceuticals' or third party's use of BMIPP. Notwithstanding anything
      in this Section 11.2, "General Claims Against Molecular Insight
      Pharmaceuticals" shall not include "IP Claims Against Molecular Insight
      Pharmaceuticals" as described in Section 11.4.

11.3  Intellectual Property Claims Against Nordion

      Molecular Insight Pharmaceuticals agrees to indemnify, defend and hold
      Nordion and its Affiliates and their respective directors, officers,

<PAGE>

                                       13

      employees and agents, harmless from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorneys' fees) resulting from any third party claims or suits arising
      out of any proceeding instituted by or on behalf of a third party based
      upon a claim that the Process, method of manufacture, use or sale of the
      Reference Standards, Precursors or BMIPP infringes a United States or
      Canadian patent or any other intellectual property or proprietary right of
      a third party ("IP Claims Against Nordion"). Notwithstanding the
      foregoing, to the extent the Process or method of manufacture is developed
      or contributed by Nordion, Molecular Insight Pharmaceuticals will not be
      required to indemnify, defend or hold harmless Nordion or its Affiliates,
      and their respective directors, officers, employees and agents from and
      against IP Claims Against Nordion.

11.4  Intellectual Property Claims Against Molecular Insight Pharmaceuticals

      Nordion agrees to indemnify, defend and hold harmless Molecular Insight
      Pharmaceuticals and its Affiliates, and their respective directors,
      officers, employees and agents from and against any damages, claims,
      liabilities and expenses (including, but not limited to, reasonable
      attorney's fees) resulting from any third party claims or suits arising
      out of any proceeding instituted by or on behalf of a third party based
      upon a claim that the Background Technology, the method of manufacture of
      BMIPP or the Process, to the extent developed or contributed by Nordion,
      infringes a United States or Canadian patent or any other intellectual
      property or proprietary right of a third party ("IP Claims Against
      Molecular Insight Pharmaceuticals").

11.5  Infringement

      In the event that any portion of the Background Technology or technology
      developed or contributed by Nordion under this Agreement becomes the
      subject of a claim for a patent, copyright or other industrial or
      intellectual property rights infringement action by a third party, Nordion
      may,

      (i)   if such technology was contributed by Nordion, procure the right to
            continue using the radiolabelling technology within a reasonable
            time not to exceed sixty (60) days; or

      (ii)  modify the Process (to the extent developed or contributed by
            Nordion) to become non-infringing; or

      (iii) if neither (i) nor (ii) are possible, upon written notice to
            Molecular Insight Pharmaceuticals immediately cease its activities
            and/or terminate this Agreement.

      The cost and expense of any opinion of counsel sought by Nordion under
      this section shall be borne by Nordion. Nordion reserves the right to
      control and direct the defense and/or settlement of such claim with legal
      counsel of its choosing; provided, however, that it may not settle such

<PAGE>

                                       14

      claims without the prior written consent of Molecular Insight
      Pharmaceuticals, which shall not be unreasonably withheld or delayed;
      provided, further that no such consent from Molecular Insight
      Pharmaceuticals shall be required if such settlement includes a full
      release of Molecular Insight Pharmaceuticals.

      In the event that any portion of the Process that was developed or
      contributed by Molecular Insight Pharmaceuticals becomes the subject of a
      claim for a patent, copyright or other industrial or intellectual property
      rights infringement action by a third party, Molecular Insight
      Pharmaceuticals may, (i) within a reasonable time not to exceed sixty (60)
      days procure the right to continue using the Process or technology, (ii)
      modify the Process, to the extent contributed by Molecular Insight
      Pharmaceuticals, to become non-infringing or (iii) if neither (i) nor (ii)
      are reasonably possible, Molecular Insight Pharmaceuticals may terminate
      this Agreement upon written notification to Nordion. Molecular Insight
      Pharmaceuticals reserves the right to control an direct the defense and/or
      settlement of such claims with legal counsel of its choosing; provided,
      however, that it may not settle such claims without the prior written
      consent of Nordion, which shall not be unreasonably withheld or delayed;
      provided, further that no such consent from Nordion shall be required if
      such settlement includes a full release of Nordion.

11.6  Indemnification Procedures

      A party (the "indemnitee") which intends to claim indemnification under
      this Article 11 shall promptly notify the other party (the "Indemnitor")
      in writing of any action, claim or other matter in respect of which the
      Indemnitee or any of its directors, officers, employees or agents intend
      to claim such indemnification; provided, however, the failure to provide
      such notice within a reasonable period of time shall not relieve the
      Indemnitor of any of its obligations hereunder except to the extent the
      Indemnitor is materially prejudiced by such failure. The Indemnitor shall
      be entitled to control the defense of and/or settle any such action, claim
      or other matter. The Indemnitee agrees to the complete control of such
      defense or settlement by the Indemnitor, provided, however, any settlement
      of such claims shall require the Indemnitee's prior written consent unless
      such settlement includes a full release of the Indemnitee, in which case
      no consent shall be required. The Indemnitee and its directors, officers,
      employees and agents shall co-operate fully with the Indemnitor and its
      legal representatives in the investigation and defence of any action,
      claim or other matter covered by this indemnification. The Indemnitee
      shall have the right, but not the obligation, to be represented by counsel
      of its own selection and at its own expense.

<PAGE>

                                       15

                       ARTICLE 12 - PATENTS AND TECHNOLOGY

12.1  Ownership of Work Performed

      The portion of the Process as developed or contributed by Molecular
      Insight Pharmaceuticals shall be the sole and exclusive property of
      Molecular Insight Pharmaceuticals. Except to the extent the Process is
      developed or contributed by Molecular Insight Pharmaceuticals, Molecular
      Insight Pharmaceuticals agrees and acknowledges that any and all ideas,
      technology, method, data, information, inventions, improvements,
      derivative works and works of authorship conceived, written, created or
      first reduced to practice in the performance of the development of the
      Process, Background Technology and improvements to the Background
      Technology during the term of this Agreement, shall be the sole and
      exclusive property of Nordion.

                         ARTICLE 13 - REGULATORY MATTERS

13.1  Regulatory Status

      Upon Nordion's reasonable request, Molecular Insight Pharmaceuticals shall
      provide updates to Nordion on (i) the progress of Clinical Trials related
      to BMIPP, and (ii) submissions to the FDA and other jurisdictions and
      regulatory agencies for marketing authorization with respect to BMIPP.

13.2  Molecular Insight Pharmaceuticals Responsibilities

      It shall be the responsibility of Molecular Insight Pharmaceuticals or its
      designee to file, obtain and maintain an IND, registrations, listings,
      authorizations and approvals as the FDA or any other applicable
      governmental entity may require to enable use of BMIPP in Clinical Trials
      in the United States. Nordion shall provide directly to Molecular Insight
      Pharmaceuticals, or at Nordion's discretion for the purpose of protection
      of its proprietary technology with respect to the manufacture of the
      Isotope, directly to the regulatory authority all required information in
      its possession necessary to assist Molecular Insight Pharmaceuticals in
      filing, obtaining and maintaining all licenses, registrations, listings,
      authorizations and approvals of any governmental entities necessary for
      the use of BMIPP in support of Molecular Insight Pharmaceuticals' BMIPP
      NDA submission.

13.3  Nordion Responsibilities

      Nordion shall be responsible for obtaining and maintaining all necessary
      Facility licenses, registrations, authorizations and approvals which are
      necessary to develop, manufacture, handle, store, label, package,

<PAGE>

                                       16

      transport and ship BMIPP under cGMP conditions and other regulatory
      requirements including, but not limited to, the use and handling of
      radioactive materials.

      At Nordion's expense, Nordion shall update its existing 1-123 bulk
      chemical or facility description Drug Master File ("DMF") with the FDA as
      may be required for Molecular Insight Pharmaceuticals' NDA for BMIPP in
      accordance with Schedule A. Nordion hereby grants Molecular Insight
      Pharmaceuticals a right of reference to such DMF, and upon request shall
      provide a letter of access to the DMF allowing regulatory review of the
      DMF by the FDA in conjunction with Molecular Insight Pharmaceuticals'
      BMIPP submissions. At Nordion's expense, Nordion shall apply for and seek
      a DMF for BMIPP in accordance with Schedule A.

13.4  Government Inspections, Compliance Review and Inquiries

      Upon request of any governmental entity or any third party entity
      authorized by a governmental entity, such entity shall, for the purpose of
      regulatory review, have access to observe and inspect the (i) Facility,
      (ii) procedures used for the storage of Reference Standards and Precursor,
      and (iii) manufacturing, testing, storage and shipping of BMIPP, including
      Process development operations, and auditing the Facility for compliance
      with cGMP and/or other applicable regulatory standards. Nordion shall give
      Molecular Insight Pharmaceuticals prompt written notice of any upcoming
      inspections or audits by a governmental entity of the Facility or any of
      the foregoing and shall allow Molecular Insight Pharmaceuticals to
      participate in such audits by being present at any FDA close out meeting
      and shall provide Molecular Insight Pharmaceuticals with a written summary
      of such inspection or audit following completion thereof. Nordion agrees
      to use commercially reasonable efforts to promptly rectify or resolve any
      deficiencies noted by a government entity in a report or correspondence
      issued to Nordion.

13.5  Access to the Facility

      Molecular Insight Pharmaceuticals shall have reasonable access to the
      Facility at least once per calendar quarter during the Development Phase
      for the purpose of observing Process development relating to BMIPP.
      Molecular Insight Pharmaceuticals shall provide to Nordion at least five
      (5) business days prior written notice of requested access to the Facility
      for the purpose of this Section. All such information disclosed to
      Molecular Insight Pharmaceuticals or its employees or agents, shall be
      deemed to be Nordion's Confidential Information as such term is defined in
      Section 14.1 of this Agreement.

13.6  Recalls

<PAGE>

                                       17

      Molecular Insight Pharmaceuticals shall notify Nordion promptly if BMIPP
      is the subject of a recall or correction (a "Recall"), and Molecular
      Insight Pharmaceuticals and/or its designee shall have sole responsibility
      for the handling and disposition of such Recall. Molecular Insight
      Pharmaceuticals and/or its designee shall bear the costs of any Recall of
      BMIPP unless and to the extent such Recall shall have been the result of
      Nordion's or its employees acts of omissions or any product defects for
      which Nordion is responsible in which case Nordion shall to such extent be
      responsible for all of Molecular Insight Pharmaceuticals' out-of-pocket
      costs incurred for:

      (i)   notification of recall to Nordion and third parties;

      (ii)  return shipment of any defective BMIPP to Nordion; and

      (iii) replacement of BMIPP.

      In the event that Nordion disputes Molecular Insight Pharmaceuticals'
      determination that the fault is due to Nordion and/or to its agent, the
      parties will select a mutually agreeable outside consulting firm which
      will be instructed to review the applicable information and data and to
      confirm or dissent from Molecular Insight Pharmaceuticals' determination.
      If the consulting firm confirms Molecular Insight Pharmaceuticals'
      determination, Nordion will pay the fees of such consulting firm. If the
      consulting firm dissents from Molecular Insight Pharmaceuticals'
      determination Nordion will not have the obligations set forth herein with
      respect to the Recall and Molecular Insight Pharmaceuticals will pay the
      fees of such consulting firm. Molecular Insight Pharmaceuticals and/or its
      designee shall maintain records of all sales, shipping records of BMIPP
      and customers in sufficient detail to adequately administer a Recall for
      the period of time as required by applicable regulation.

13.7  New Regulatory Requirements

      Each party shall promptly notify the other of new regulatory requirements
      of which it becomes aware which are relevant to the manufacture of BMIPP
      under this Agreement and which are required by the FDA and other
      applicable governmental entities and the parties shall confer with each
      other with respect to the best means to implement and comply with such
      requirements.

13.8  Records

      Nordion shall maintain all records necessary to evidence compliance with
      (i) all applicable laws, regulations and other requirements of applicable
      governmental entities in the United States and Canada relating to the
      supply and manufacture of BMIPP; (ii) the Specifications; and (iii)
      obligations under this Agreement. All such records shall be maintained by

<PAGE>

                                       18

      Nordion for at least two (2) years after termination or expiration of this
      Agreement. Nordion shall provide to Molecular Insight Pharmaceuticals
      reasonable access to such records upon request. Prior to destruction of
      any record after such time, Nordion shall give written notice to Molecular
      Insight Pharmaceuticals. Molecular Insight Pharmaceuticals shall have the
      right to request that Nordion maintain such records in an off site storage
      facility for such longer periods as Molecular Insight Pharmaceuticals
      requests, provided that Molecular Insight Pharmaceuticals pays all costs
      associated with such off site storage.

                          ARTICLE 14 - CONFIDENTIALITY

14.1  Confidentiality and Exceptions

      During the term of this Agreement and for a period of ten (10) years
      thereafter, each party hereto shall maintain in confidence the content of
      the transactions contemplated herein, all technology including Background
      Technology and improvements thereto, Nordion proprietary technology,
      Molecular Insight Pharmaceuticals proprietary technology, trade secrets,
      know-how, data, processes, methods, techniques, formulas and test data
      (collectively "Confidential Information") and other information disclosed
      to such party by the other party which is identified as "Confidential
      information" by the disclosing party. This obligation of confidentiality
      shall not apply to the extent that it can be established by the party in
      receipt of such information, that the information:

      (i)   was already known to the receiving party at the time of disclosure;

      (ii)  was generally available to the public or otherwise part of the
            public domain at the time of its disclosure;

      (iii) became generally available to the public or otherwise part of the
            public domain after its disclosure to the receiving party through no
            act or omission of the receiving party;

      (iv)  was disclosed to the receiving party by a third party who was not
            known or ought to be known to the receiving party to have
            obligations restricting disclosure of such information; or

      (v)   was independently developed by the receiving party without any use
            of Confidential Information of the disclosing party.

      Each party agrees that it will take the same steps to protect the
      confidentiality of the other party's Confidential Information as it takes
      to protect its own proprietary and confidential information, which shall
      in no event be less than commercially reasonable steps. Each party, and
      its employees and agents shall protect and keep confidential and shall not
      use, publish or otherwise disclose to any third party, except as permitted
      by this Agreement, as necessary to perform its obligations hereunder, or

<PAGE>

                                       19

      with the other party's written consent, the other party's Confidential
      Information.

      It is agreed that disclosure of data, information or technology by
      Molecular Insight Pharmaceuticals or Nordion to the other under this
      Agreement shall not constitute any grant, option or license under any
      patent, technology or other rights, held by Molecular Insight
      Pharmaceuticals or Nordion. Any use of the data, information and
      technology provided by Molecular Insight Pharmaceuticals to Nordion which
      relates to Precursor, Reference Standards or radiolabelling of Precursor
      shall be for the limited purpose of assisting Nordion in carrying out its
      obligations under this Agreement. All data, information, or technology
      supplied by one party to the other to assist in carrying out the
      obligations hereunder shall remain the property of such party and shall be
      returned to the other party upon termination of this Agreement.

                     ARTICLE 15 - DISCLOSURE OF INFORMATION

15.1  Authorized Disclosure

      Notwithstanding section 14.1 each party may disclose Confidential
      Information to the extent such disclosure is reasonably necessary for
      prosecuting or defending litigation and/or complying with applicable
      government laws or regulations, provided that if a party is required by
      law or regulation to make any such disclosure of the other party's
      Confidential Information it will give reasonable notice to the other party
      of such disclosure requirement.

                        ARTICLE 16 - TERM AND TERMINATION

16.1  Initial Term

      The term of this agreement shall commence upon the Effective Date and,
      unless terminated earlier pursuant to this agreement, or extended upon
      mutual agreement of the parties, shall expire on December 31, 2005.

16.2  Termination Without Cause

      Molecular Insight Pharmaceuticals may terminate this Agreement without
      cause or penalty upon thirty- (30) day's prior written notice to Nordion.
      Upon such termination, Nordion shall be entitled to retain all amounts
      paid by Molecular Insight Pharmaceuticals and Molecular Insight
      Pharmaceuticals shall pay to Nordion any amounts due and/or earned but not
      yet paid.
<PAGE>

                                       20

16.3  Termination for Breach

      This Agreement may be terminated by either party in the event of the
      material breach by the other party of the terms and conditions hereof;
      provided, however, the other party shall first give to the breaching party
      written notice of the proposed termination of this Agreement (a "Breach
      Notice"), specifying the grounds therefor. Upon receipt of such Breach
      Notice, the breaching party shall have such time as necessary, but in any
      event not more than thirty (30) days to cure such breach. Notwithstanding
      the foregoing, if the breaching party does not cure such breach within
      such cure period, the other party may terminate the Agreement without
      prejudice to any other rights or remedies which may be available to the
      non-breaching party.

16.4  Bankruptcy

      This Agreement may be terminated by a party in the event the other party
      files a petition in bankruptcy, is adjudicated a bankrupt, makes an
      assignment for the benefit of its creditors, or otherwise seeks relief
      under or pursuant to any bankruptcy, insolvency or reorganization statute
      or proceeding, or if a petition in bankruptcy is filed against it which is
      not dismissed within ninety (90) days or proceedings are taken to
      liquidate the assets of such party.

                             ARTICLE 17 - SURVIVAL

17.1  Consequences or Termination or Expiration

      Upon expiration or termination of this Agreement, the obligations of the
      parties under Articles 9, 10, 11, 12, 14, 15, 19 and 24 shall survive such
      expiration or termination in accordance with its terms.

                               ARTICLE 18-NOTICES

18.1  Any notice to be sent to a party hereunder shall be forwarded to:

      Nordion at:     MDS Nordion
                      447 March Road
                      Ottawa, ON
                      K2K 1X8
      Attention:      Senior Vice President, Nuclear Medicine
                      Fax:

      Molecular Insight Pharmaceuticals at:

<PAGE>

                                       21

                      Molecular Insight Pharmaceuticals, Inc.
                      160 Second Street
                      Cambridge, MA
      Attention:      Chief Operating Officer
                      Fax: 617-492-5664

      Any notice required or authorized to be given by a party to the other in
      accordance with the provisions of this Agreement shall, unless otherwise
      specifically stipulated, be in writing and delivered personally, by a
      nationally recognized overnight courier, or if by electronic facsimile
      confirmed by certified or registered mail. Notice shall be deemed
      delivered upon receipt.

                         ARTICLE 19 - LIMITED LIABILITY

19.1  Disclaimer

      In no event shall either party be liable to the other party for indirect,
      punitive, contingent, incidental, special or consequential damages.

19.2  Limitation of Product Warranty

      MOLECULAR INSIGHT PHARMACEUTICALS ACKNOWLEDGES THAT NORDION IS
      MANUFACTURING AND SUPPLYING BMIPP TO MEET SPECIFICATIONS. EXCEPT AS
      EXPRESSLY SET OUT IN THIS AGREEMENT, NORDION HEREBY DISCLAIMS ALL OTHER
      WARRANTIES OR CONDITIONS, WHETHER EXPRESS OR IMPLIED, STATUTORY OR
      OTHERWISE, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OR
      CONDITIONS OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

                   ARTICLE 20 - ASSIGNMENT AND SUBCONTRACTING

20.1  No Assignment

      This Agreement shall enure to the benefit of and shall be binding upon the
      heirs, executors, administrators, successors and permitted assigns of the
      parties. Neither Nordion nor Molecular Insight Pharmaceuticals shall
      assign this Agreement or any portion of this Agreement without the written
      approval of the other party, which approval shall not be unreasonably
      withheld; provided, however, that Molecular Insight Pharmaceuticals may
      assign this Agreement without Nordion's consent in connection with the
      sale of all or substantially all of its stock or assets to a third party
      or in connection with a merger, consolidation or similar transaction.

                             ARTICLE 21 - COMPLIANCE

21.1  Compliance with Laws

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       22

      This Agreement and Nordion's and Molecular Insight Pharmaceuticals'
      obligations hereunder shall be carried out in compliance with all
      applicable laws, by-laws, rules, regulations and orders of all applicable
      Federal, State, Provincial and Municipal governments.

                             ARTICLE 22 - NON-WAIVER

22.1  Non-Waiver of Rights

      Failure by either party to enforce at any time any of the provisions of
      this Agreement shall not be constructed as a waiver of its rights
      hereunder. Any waiver of a breach of any provision hereof shall not be
      effective unless in writing and shall not affect either party's rights in
      the event of any additional breach.

22.2  Force Majeure

      Neither party shall be liable to the other for failure to perform or delay
      in performing its obligations under this Agreement by virtue of the
      occurrence of an event of Force Majeure. In the event of Force Majeure,
      the party affected shall promptly notify the other and shall exert
      commercially reasonable efforts to eliminate, cure or overcome such event
      and to resume performance of its obligations. In the event such Force
      Majeure affecting either party continues for more than thirty (30) days
      the party not subject of the Force Majeure may terminate this Agreement.
      "Force Majeure" shall mean an occurrence which prevents, delays or
      interferes with the performance by a party of any of its obligations
      hereunder if such event occurs by reason of any act of God, flood, power
      failure, fire, explosion, casualty or accident, or war, revolution, civil
      commotion, acts of public enemies, blockage or embargo, or any law, order
      or proclamation of any government, failure of suppliers or usually
      supplier to provide materials, equipment or machinery, interruption of or
      delay in transportation, strike or labor disruption.

                             ARTICLE 23 - INSURANCE

23.1  Product Liability Insurance

      During the term of this Agreement and for a period of one (1) year
      thereafter Molecular Insight Pharmaceuticals at its own expense shall
      provide and maintain a products liability insurance policy issued by a
      reputable insurance company with respect to BMIPP. Such policy shall add
      Nordion as an additional insured and shall have a limit of liability of
      not less than [*************] United States dollars ($[*********]US) per
      occurrence and in the aggregate. Molecular Insight Pharmaceuticals shall

<PAGE>

                                       23

      be solely responsible for any deductible or retention associated with this
      policy and such deductible or retention amounts shall not affect Nordion's
      interests. The policy shall contain a cross liability clause and shall
      provide for severability of interest such that breach of a policy
      condition committed by any one insured shall not adversely affect the
      rights of the other insured. Nordion shall be provided thirty (30) days'
      prior written notice of any material change to the policy and such change
      shall be subject to Nordion's prior written consent, which consent shall
      not be unreasonably withheld. Nothing contained in this Section shall be
      deemed to limit in any way the indemnification provisions contained in
      this Agreement.

                            ARTICLE 24 - PUBLICATION

24.1  Publicity

      The parties agree that, except as may otherwise be required by applicable
      laws, regulations, rules or orders or in connection with obtaining
      regulatory approvals for BMIPP, no information concerning this Agreement
      and the transactions contemplated herein shall be made public by either
      party without the prior written consent of the other, which consent shall
      not be unreasonably withheld or delayed. In the event either party decides
      to issue a press release announcing the execution of this Agreement, it
      shall not do so without the prior written approval of the other party.

      A copy of any proposed press release shall be provided to the other party
      for approval at least three (3) business days prior to any proposed
      release.

      In the event that this Agreement or any portion of its contents is
      required to be disclosed by Molecular Insight Pharmaceuticals or Nordion
      pursuant to Security Exchange Commission rules or regulations or other
      federal or state authorities, Molecular Insight Pharmaceuticals or
      Nordion, as the case may be, shall provide reasonable notice to the other
      prior to any such disclosure in order that, to the extent possible while
      enabling the party to comply with the applicable laws, rules and
      regulations, the content so disclosed does not include information which
      may reasonably be considered by the other as confidential, proprietary
      and/or commercially sensitive information.

                         ARTICLE 25 - DISPUTE RESOLUTION

25.1  Dispute Resolution

      Except as otherwise set out, in the event that at any time during the term
      of this Agreement, a disagreement, dispute, controversy or claim should
      arise relating to the (i) interpretation of or performance under this

<PAGE>

                                       24

      Agreement or the attribution of liability or breach thereof; or (ii)
      scientific or technical issues in connection with Nordion or Molecular
      Insight Pharmaceuticals' performance under this Agreement, the parties
      will attempt, in good faith, to resolve their differences for a period of
      thirty (30) days following written notice from one party to the other
      specifying such dispute(s). In the event the parties are unable to work
      out a resolution of the issue during such 30-day period, either party
      shall be free to take any action and seek any remedy it may have at law or
      in equity including specific performance and injunctive relief.

                       ARTICLE 26 - INDEPENDENT CONTRACTOR

26.1  No Joint Venture

      The parties agree that with respect to the transactions contemplated
      herein that they shall both be acting as independent contractors and
      nothing herein shall constitute the parties as entering into a joint
      venture or partnership, nor shall anything herein constitute either party
      as an agent of the other for any purpose whatsoever.

                            ARTICLE 27 - SEVERABILITY

27.1  Invalid Provisions

      If any provision or term of this Agreement is found unenforceable under
      any of the laws or regulations applicable thereto, all other conditions
      and provisions of this Agreement shall nevertheless remain in full force
      and effect. Upon such determination that any term or other provision is
      invalid, illegal or incapable of being enforced, the parties hereto shall
      negotiate in good faith to modify this Agreement to effect the original
      intent of the parties as closely as possible in a mutually acceptable
      manner, in order that the transaction contemplated hereby be consummated
      as originally contemplated to the greatest extent possible.

                             ARTICLE 28 - AGREEMENT

28.1  Entire Agreement

      This Agreement, including the Schedules hereto which are incorporated
      herein, constitute the entire agreement of the parties with respect to the
      subject matter hereof and supersedes all proposals, oral or written, and
      all negotiations, conversations, or discussions. This Agreement may not be
      modified, amended, rescinded, canceled or waived, in whole or in part,
      except by written amendment signed by both parties hereto.

<PAGE>

                                       25

                                ARTICLE 29 - LAW

30.1  Applicable Law

      This Agreement shall be governed and construed in accordance with the laws
      of the Province of Ontario, Canada, without reference to its principles on
      conflict of laws. The application of the United Nations Convention for the
      International Sale of Goods is expressly excluded.

<PAGE>

                                       26

      IN WITNESS WHEREOF the parties hereto have executed this agreement as of
the date first above written.

MDS Nordion,                             Molecular Insight Pharmaceuticals, Inc.
a division of MDS (Canada) Inc.

By: /s/ Gerry Vantellingen              By: /s/ John W. Babich
    ---------------------------            ------------------------

#63441 v1 - Agreement/Molecular Insight/Final
<PAGE>

                                   SCHEDULE A

                                  Scope of Work

<TABLE>
<CAPTION>
                                                                                               Commence
                                         ACTIVITY                                Duration   -------------
                                         --------                                --------    Y weeks from
                                                                                  X weeks   Effective Date
                                                                                 --------   --------------
<S>                                                                              <C>        <C>
1. Activity 1 - Technology Transfer

   a) Review Customer Supplied Documentation                                         2             1
   b) Write, review and approve Preliminary Safety Analysis Report(PSAR)             3             2
   c) Experimental Design for Scale-Up                                               2             2
   d) Scale-Up to 1 Ci (up to 10 runs maximum)
      i)   Show reproducibility of procedure                                         5             5
      ii)  Increase yield to 80% after quenching and isolation
           (commercially reasonable best efforts)

      iii) Verify autoclavability of formulation. Establish excipient
               ranges

   e) Scale up to 4 Ci (up to 5 runs)                                                3            10
   f) Document experiments and archive data (HPLC traces,                            3            13
      logbooks, etc.)
   Milestone 1 : Complete Technology Transfer                                        0            16

2. Activity 2- Reformulation and Purification

   a) Develop HPLC Separation Method                                                 6             4
   b) Develop Automation: sample transfer and collection                             4             4
   c) Develop compatibility of HPLC collected fraction with                          2             4
      Formulation. Establish excipients
   d) IQ/OQ and validate autoclave.                                                  5             4
   e) IQ/OQ/PQ for HPLC and equipment.                                               6            16
   f)  Draft Master Batch Record for Molecular Insight approval.                     2            19
   Milestone 2: Complete Reformulation and Purification                              0            21

3. Activity 3- Develop Dispensing Equipment

   a) Develop dispensing setup for 30 vial capability                               10             9
      - IQ/OQ/PQ Dispensing
      - Seal and crimp

   b) Develop container/ closure system                                              8            11
      - Complete closure test and integrity
      - Complete recoverability of dose from Container Test
   c) Establish Class 100 conditions for dispensing box at vial                      1            19
      opening.
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   d) IQ/OQ/PQ Shielded boxes (SB)                                                   2            20
      - calibrate gauges
      - establish airborne I-123 detection system
   e) IQ/OQ/PQ Laminar Air Flow (LAF) Assembling Area.   .                           2            20
   f) Initiate Environmental Monitoring in LAF, SB and                               3            20
      Controlled Access Room,
   Milestone 3: Complete Dispensing Equipment Development                            0            22

4. Activity 4- Develop Q.C. Test Methods

   a) HPLC Method for Final Product.                                                 4            22
      - verify                      1) BMIPP
                                    2) UDCA
                                    3) Any other identified
                                 impurities as per specifications in
                                 Schedule F.
      -   establish 1) Radiochemical Purity
                     2) Chemical purity - Quantitative method
      Note: this is a method transferred from Molecular Insight
      -   Write and approve Standard Test Method (STM)
   b) IQ/OQ/PQ Dose Calibrator                                                       2            26
       Write and Approve STM
   c) Gamma Spectroscopy                                                             1            26
      -   Calibration Protocol
      -   NIST traceability
      -   159 keV Identification (ID) for I-123
      -   Write.and approve STM
   d) Endotoxin Test (USP)                                                           1            28
      -   Dilution to overcome Inhibition/Enhancement
      -   Maximum valid dilution
      -   Qualification of test method
      -   Write and approve STM
   e) Sterility Test (USP)                                                           1            28
      -   Establish sampling size
      -   Write and approve STM
   f) Product Release Form (PRF)                                                     1            29
      -   Identify all documents necessary for batch release
   Milestone 4: Complete QC Test Methods Development                                 0            30

5. Activity 5- Validation of New Process

   a) Write and approve Master Validation Plan                                       8             4
      -    Equipment: Analytical and Process
      -    Analytical Methods
      -    Process
      -    Final Product Stability
   b) Method Transfer Validation                                                     6            30
      -    Analytical Methods
      -    References Standards (shelf-life; ID)
      -    Precursor (ID; shelf-life)
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   c) Validation Protocols                                                           2            36
   d) Six Process Runs to fine tune process                                          6            28
   e) Train Operators                                                                6            28
      - 3 Production technicians

      - 3 QC/QA

      - 2 Packaging
   Milestone 5: Complete Validation of New Process                                                34

6. Activity 6- Perform GMP Equivalency Run (Validation Runs)                         3            34

   a) Perform three runs (1 Ci of I-123)                                             3            37
   b) Compile all data for validation files                                          0            40
   Milestone 6: Complete Validation Runs

7. Activity 7- Prepare Development Report

   a) Document all experimentation                                                   6            31
   b) Archive all data/logbooks                                                      6            31
   c) Write and approve Development Report                                           6            39
      - Process Description and Development

      - Master Formula

      - Impurities profiles (standards to be provided by

        Molecular Insight)
      - Excipient Ranges

      - Final Product Specifications

      - Scale-Up rationale

      - Equivalence to previous formulation ( to be done in
        conjunction with Molecular Insight at their cost)

      - Qualification of Reference Standards to be done by
        Molecular Insight

      - Precursor made under cGMPs to be provided by
        Molecular Insight

      - Analytical Method and Validation to be done by
        Molecular Insight

      - Bioburden Profiles for Raw Material

      - Environmental data - house isolates

      - Molecular insight to provide stability indicating
        methods for final product

      - Define Utilities

      - Cleaning Protocol
   Milestone 7: Submit Development Report                                                         45

8. Activity 8- DMF / CMC Package

   a) Provide SOPs/STMs for CMC section of NDA                                       3            37
   b) Provide flowcharts                                                             3            37
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                  <C>          <C>
   c) Establish Review and Approval responsibility for                               3            37
      documents
   d) Establish Recall procedure                                                     3            37
   e) Establish responsibilities of                                                  3            37
      1) Deviations

      2) Change Control

      3) Product Release

      4) Failure Investigation

      5) Out-of-Spec Investigation

      6) Draft required procedures

   Milestone 8: DMF/CMC Package Complete                                                          40

9. Activity 9- Prepare for PAI

   a) audit for cGMP compliance (with customer)                                      3            40

   b) Review findings and establish action plan                                      3            40

   c) Review costs of ongoing and enhanced compliance (to be                         3            40
      billed to Molecular Insight as required)

      NOTE: PAI readiness will
      require additional staffing and/or consultants that will be charged
      to Molecular Insight.
   Milestone 9: Ready for PAI                                                                     43
</TABLE>

   Pcdocs 62635
<PAGE>

                                   SCHEDULE B

              FACILITY RESOURCES FOR CONTRACT MANUFACTURE OF BMIPP

THE FOLLOWING EQUIPMENT IS USED TO MANUFACTURE BMIPP:

-     Laminar Flow Hood for reagent and equipment preparation

-     Three Lead shielded glove boxed with HEPA filtration and Nuclear
      Ventilation

      -     Box 1 reaction, separation, formulation box containing
            semi-preparative automated HPLC for drug substance isolation

      -     Box 2 has the function to act as a dispensing area. The
            dispensing environment is class 100

      -     Box 3 is the terminal sterilization box containing an
            autoclave and a remote handling ball and tong manipulator

-     Specialized shielding assemblies are used for the safe transport of
      formulated unit dose radiopharmaceuticals

-     Fume hood with nuclear ventilation for QC analysis

-     HPLC equipment for QC analysis

-     Dose calibrator

-     Particle check station

-     Gamma Spectroscopy system

-     Refrigerator

SOME GENERAL FEATURES OF THE MANUFACTURING AREA AND SUPPORT SERVICES ARE:

-     The room is environmentally and radiation monitored

-     There are waste handling systems in place to deal with chemical waste
      streams as well as solid and liquid radioactive wastes

-     The entire manufacturing environment is cGMP regulated

-     Qualified and trained staff with experience in diagnostic
      radiopharmaceutical manufacture are employed

-     The entire manufacturing facility is supported by a calibration department

-     A fully outfitted microbiology lab is available for microbiological and
      environmental tests (Most importantly LAL tests for pyrogenicity)

-     There is an attached microbiology clean room used for sterility tests and
      filtration.

-     This clean room contains a class 100 glove box.

NOTE: EQUIPMENT OTHER THAN THAT LISTED ABOVE (SUCH AS HOT CELLS ETC.) MAY BE
USED DURING DEVELOPMENT

<PAGE>

                                   SCHEDULE C

                         BMIPP PRECURSOR SPECIFICATIONS

Note: 1. Supplied by Molecular Insight Pharmaceuticals and MDS Nordion to do
identification only

<PAGE>

                                   SCHEDULE D

                       REFERENCE STANDARDS SPECIFICATIONS

Note: 1. Supplied by Molecular Insight Pharmaceuticals and MDS Nordion to do
identification only

<PAGE>

                               SPECIFICATION SHEET

TCI America, 9211 N Harborgate St,
Portland, OR 97203                 Version Date 3/7/02      Form No. :SS. 057.02

Material            BMIPP (INACTIVE COMPONENT/PRECURSOR)         Code No.: Z3398

Formula: C(22)H(35)IO(2)       Molecular Wt.: 458.42        CAS No.: 116754-87-1

Synonym(s):  15-(p-Iodophenyl)-
3-methylpentadecanoic Acid                     Storage Conditions:<or=4C(degree)

<TABLE>
<CAPTION>
Frequency             Test                                 Acceptance Criteria                        Test Procedure
------------------    ----------------------------------   ---------------------------------------    -----------------------
<S>                   <C>                                  <C>                                        <C>
0,3,6,9, 12,          Appearance                           Colorless or white crystals or powder      SLT QC 339
18,24,36,
48, 60mo

0-60 months           Identification              FTIR     Identical to reference standard            SLT QC 327

After manufacture                                 UV-VIS   Identical to reference standard            SLT QC 371

0 - 60 months                                     HPLC     Retention time corresponds with that of    SLT QC 358
                                                           the reference standard within +/- 3%

0-60 months           Purity Assay (HPLC)                  > or = 95%                                 SLT QC 358

After manufacture     Purity, Melting point                51-56(degree)C                             SLT QC 322

After manufacture     Purity, Water analysis (KF)          Report results                             SLT QC 329

0 - 60 months         Impurities, HPLC Related             < or = 2.0 % any single species            SLT QC 358

0 - 60 months         Methyl 15-(p-Iodophenyl)-3           < or = 0.1%                                SLT QC 358
                      Methylpentadecanoate

After manufacture     Heavy metals                         < or = 20 ppm                              SLT QC 332 (Method II)

After manufacture     Residual Solvents

                                   Hexane                  < or = 290 ppm                             SLT QC 340

                                   Methanol                < or = 3000 ppm                            SLT QC 340

                                   Ethyl Acetate           < or = 5000 ppm                            SLT QC 340

                                   Ethanol                 < or = 5000 ppm                            SLT QC 340

                                   Isopropanol             < or = 5000 ppm                            SLT QC 340
After manufacture     Organic Volatile Impurities

                                   Methylene Chloride      < or = 500 ppm                             SLT QC 340
</TABLE>

<PAGE>

                                   SCHEDULE E

                              BMIPP SPECIFICATIONS
<PAGE>

SPECIFICATION SHEET                                                 Page 1 of 1

                        DRUG PRODUCT SPECIFICATION SHEET

<TABLE>
<S>                                                  <C>                <C>
Molecular Insight, 160 Second ST, Cambridge, MA      Version Date       (ACTIVE COMPONENT)
02142                                                 4/13/04
</TABLE>

Material                          [(123)I]-BMIPP              CODE NO.: MIP 1000

Formula: C(22)H(35)IO(2)           Molecular Wt.: 454.42    CAS No.: 116754-87-1

Synonym(s):   [(123)I]-15-(p-Iodophenyl)-3-methylpentadecanoic Acid

<TABLE>
<CAPTION>
            TEST                  ACCEPTANCE CRITERIA          TEST METHOD                TESTING SCHEDULE
<S>                        <C>                                 <C>                        <C>
Appearance                     Clear, Colorless Solution       Visual observation         Test Completed prior
                                                               STM 12                     to release of drug
Radionuclide Identity      Gamma-Photon emission at 159 +/-    Gamma ray Spectroscopy,    Test Completed prior
                            5 keV                              STM 23
                                                                                          to release of drug
Radionuclide Impurity      <or= 2.5% I-125 at TOC              Gamma ray Spectroscopy,    Confirmation Test of
                           <or= 110 (mu)Ci/mL I-125 at TOC     STM 21                     component Nal, After
                                                                                          decay of I-123, 2
                                                                                          weeks after release
Radioactivity                     3.6 to 4.4 mCi/mL            Dose Calibrator            Test Completed prior
Concentration                                                  STM 27                     to release of drug
Radiochemical Identity*       R(r) value between 0.30 to       Normal phase TLC           Test Completed prior
                              0.50
                                                               STM 16                     to release of drug
Radiochemical Purity            >95% as I-123-BMIPP            Reverse phase HPLC         Test Completed prior
                                                               Radiometric detector       to release of drug
                                                               STM 17
Chemical Concentration            0.36 to 0.44 mg/ml           Reverse phase HPLC         Test Completed prior
                                                               UV-VIS detector            to release of drug
                                                               STM 17
Radiochemical Impurity         <or= 5% as free I-123           Reverse phase HPLC         Test Completed prior
                                                               Radiometric detector       to release of drug
                                                               STM 17
Radiometric Assay for       4.5 to 5.5 mCi per (1.25 mL)       Dose Calibrator            Test Completed prior
unit dose vial              at TOC
Osmolarity                                                     STM 11                     to release of drug
                                Ratio to Saline 0.8 to         Osmometer, compare with    Test Completed prior
                                  1.0                          normal saline
                                                               STM 18                     to release of drug

pH                                 Range 8.2 to 9.2            pH paper                   Test Completed prior
                                                               STM 19                     to release of drug
Bacterial Endotoxin        <or=4.0 EU/ml                       Limulus Amebocyte Lysate
                                                               test on diluted drug
                                                               product                    Test Completed prior
                                                               STM 14                     to release of drug

Sterility                  No turbidity or growth              2 week incubation in       Test initiated
                                                               Fluid Thioglycollate       within 24 hours of release
                                                               Medium &
                                                               Trypticase Soy Broth
                                                               STM 13
Package Inspection         No damage                           Visual                     Test Completed prior
                                                               STM 15                     to release of drug
</TABLE>

Note: All STM numbers will be changed to equivalent MDS Nordion document
numbers.

* This TLC test may be replaced by HPLC.

TOC = Time of Calibration; 1500 h PT, one day after manufacture

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                PRICE SCHEDULE F

1.    FACILITY ESTABLISHMENT FEE:

      This is a one-time fee for the establishment of the facility described in
      Schedule B.

      PRICE: $[*******] US

      Note: Fee is payable upon signing of the Agreement

2.    MILESTONES PAYMENTS:

<TABLE>
<CAPTION>
   MILESTONE                   DESCRIPTION                  PRICE US$
   ---------                   -----------                  ---------
<S>                  <C>                                    <C>
Milestones 1 & 2     Technology Transfer &                  $[*******].
                     Reformulation and Purification

Milestone 3          Dispensing Equipment                   $[*******].

Milestone 4          QC Test Methods                        $[******].

Milestone 5          Validation of New Process              $[*******].

Milestone 6          GMP Validation Runs                    $[******].

Milestone 7          Development Report                     $[******].

Milestone 8          DMF/CMC Package for                    $[******].
                     BMIPP

Milestone 9          Prepare for PAI                       Not included at this
                                                     time - estimated $[******].
</TABLE>

      Notes - [***] of each Milestone payment is due upon signing of the
      Agreement, [***] when the specific Milestone is commenced and the
      remainder of each Milestone Payment is due upon completion of the
      Milestone.

3.    BATCHES FOR PHASE III CLINICAL SUPPLY:

      Price: US$ [******]. per Batch

      Notes - a)   Batch runs are ~30 doses of BMIPP of which 20 are shippable

              b)   Payment is due within 30 days of the date appearing on
                   Nordion's invoice.

 Pcdocs62680

<PAGE>

                           447 March Road               Tel: +1 613 592 2790
                           Ottawa, ON K2K 1X8           Fax: +1 613 592 6937
                           Canada                       www.mds.nordian.com

[MDS NORDION LOGO]
  Science Advancing Health

May 25, 2005

Molecular Insight Pharmaceuticals Inc.
160 Second Street
Cambridge, Massachusetts
02142
USA

Dear Sirs:

RE:   AMENDMENT #1 TO AGREEMENT BETWEEN MDS NORDION, A DIVISION OF MDS (CANADA)
      INC. (SUCCESSOR TO MDS NORDION INC.) AND MOLECULAR INSIGHT PHARMACEUTICALS
      INC. DATED THE 14th DAY OF JUNE, 2004

Reference is made to the agreement between MDS Nordion and Molecular Insight
Pharmaceuticals Inc., dated the 14th day of June 2004 (the "Agreement").

In consideration of $1.00 and other valuable consideration the receipt of
sufficiency of which is hereby acknowledged, the parties desire to extend the
terms of the Agreement.

Section 16.1 of the Agreement shall be amended in its entirety and shall read as
follows:

                "The term of this Agreement shall commence upon the Effective
                Date, and unless terminated earlier pursuant to this Agreement,
                shall expire on December 31, 2006."

All other terms and conditions in this Agreement shall remain in full force and
effect.

The foregoing amendment shall be effective as of the date first written above.

If you agree with the foregoing, please execute this agreement in the space
provided below.

Sincerely,

                                          We agree this 25th day of May, 2005
MDS NORDION                               MOLECULAR INSIGHT PHARMACEUTICALS INC.

Per: /s/ Gerry Vantellingen               Per: /s/ John E. McCray
     ----------------------------                 ------------------------------
     Name: Gerry Vantellingen                     Name: John E. McCray
     Title: Vice President, Sales                 Title: Chief Operating Officer<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                                                  Exhibit 10.14

                               RESEARCH AGREEMENT
                              AND EXCLUSIVE LICENSE

      Effective as of December 29, 1997, GEORGETOWN UNIVERSITY, a not-for-
profit corporation of the District of Columbia, having a principal address of
37th & "O" Streets, N.W., Washington, D.C. 20057 ("LICENSOR"), and ZEBRA
PHARMACEUTICALS, a Massachusetts corporation, having a principal place of
business at 38 Hartman Road, Newton, Massachusetts 02159 ("LICENSEE") agree as
follows:

                                  1. BACKGROUND

      1.1 -- LICENSOR is the owner by assignment of inventions directed
generally to cocaine analogs, and specifically piperidine analogs thereof (the
"Invention(s)").

      1.2 -- LICENSOR wishes to have the Invention(s) and related technologies
perfected and marketed at the earliest possible time in order that products
resulting therefrom may be available for public use and benefit.

      1.3 -- LICENSEE wishes to acquire a license under said Invention(s) and
Licensed Patent(s), for the purpose of undertaking development, to manufacture,
use, and sell Licensed Produce(s) in the Licensed Field of Use.

                                 2. DEFINITIONS

      2.1 -- "Patent Rights" refers to LICENSOR's rights arising from
Provisional U.S. Patent Application Serial No. 60/042,775, filed April 7, 1997,
entitled "Analogs of Cocaine" and naming as inventors Alan P. Kozikowski and
Gian Luca Araldi, including the information contained in said application with
respect to the Invention(s), any foreign patent applications corresponding
thereto, any divisions, continuations, reissues, or reexaminations thereof, and
any patent(s) issuing or granted therefrom. Such patent application(s) are the
"Licensed Application(s)" and any resulting issued patents are the "Licensed
Patent(s)."

      2.2 -- "Technology" means any existing technical data and information
provided to LICENSEE by LICENSOR or its employees or contractors relating to
Invention(s), including, without limitation, any biochemical, preclinical,
clinical, manufacturing, formulation, and scientific research information of a
confidential nature.

                                       1
<PAGE>

      2.3 -- "Licensed Product(s)" means any compound, product or part thereof
 in the Licensed Field of Use, the manufacture, use, or sale of which:

      (a) is covered by a valid claim of an issued, unexpired Licensed Patent(s)
directed to the Invention(s). A claim of an issued, unexpired Licensed Patent(s)
shall be presumed to be valid unless and until it has been held to be invalid by
a final judgment of a court of competent jurisdiction from which no appeal can
be or is taken;

      (b) is covered by any claim being prosecuted in Licensed Application(s).

      2.4 -- "Net Sales" means the gross revenue of the Licensed Product(s) in
the form in which it is sold or used, whether or not assembled (and without
excluding therefrom any components or subassemblies thereof, whatever their
origin and whether or not patent impacted) less the following items:

      (a) Import, export, excise, value added and sales taxes, plus custom
duties;

      (b) Costs of insurance, packing, and transportation from the place of
manufacture to the customer's premises or point of installation;

      (c) Normal and customary quantity and cash discounts, and

      (d) Credit for returns, allowances, or trades actually given.

      2.5 -- "Licensed Field of Use" means therapeutic and diagnostic uses of
transporters for neurotransmitters, including dopamine, serotonin and
norepinephrine, for substance abuse, obesity, depression, Parkinson's disease,
and related neuro psychological conditions or diseases.

      2.6 -- "Exclusive" means LICENSOR has not granted and shall not grant
further licenses in the Licensed Field of Use, so long as this Agreement is
fully operative.

      2.7 -- "Regulatory Approval" means any approval or clearance by any
governmental agency or agencies having authority to regulate the use or sale of
any Licensed Product(s) in the pertinent jurisdiction or territory.

      2.8 -- "LICENSEE" is understood to include all of its Affiliates. An
Affiliate of  LICENSEE shall mean any corporation or other business entity
controlled by, controlling, or under common control with LICENSEE as of the date
of this Agreement. For this purpose, "control" means direct or indirect
beneficial ownership:

      (a) Of at least fifty percent (50%) of the voting stock; or

      (b) Of at least fifty percent (50%) interest in the income of such
corporation or other business.

                                       2
<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                             3. RESEARCH AGREEMENT

      3.1 -- LICENSOR shall perform pre-clinical pharmacology and new compound
synthesis sufficient to identify, if feasible, a lead compound suitable for
development into a Licensed Product. (see attached Statement of Work and Budget)

      3.2 -- Within two months of execution of this agreement, LICENSEE agrees
to pay to LICENSOR its costs, including overhead, incurred to-date in connection
with the preparation, filing and prosecution of the Licensed Applications, which
costs have been estimated by LICENSOR to be $2,500.

      3.3 -- LICENSEE shall fund the LICENSOR's research as follows:

            (a) LICENSEE shall pay to LICENSOR, upon execution of this
Agreement, an initial amount of $[******], which shall fund LICENSOR's initial
year of research.

            (b) On the first day of both the 12th and 24th full calendar months
after the execution of this Agreement, LICENSEE shall pay to LICENSOR $[*****]
to fund an additional year of research, unless LICENSOR and LICENSEE agree that
such additional research is not necessary.

            (c) If at any time LICENSOR shall determine that any of the above
sums are inadequate to fund the research or other work necessary to permit the
development of a Licensed Product, it shall notify LICENSEE of the amount that
LICENSOR reasonably believes will be necessary to fund the remaining research.
LICENSEE shall then have 60 days to notify LICENSOR, in writing, whether it is
willing to agree to provide such additional amounts. If LICENSEE does not agree
to provide such amounts, then either party may terminate this Agreement by
written notice to the other. Such termination will not apply to any previously
developed Licensed Products.

      3.4 -- LICENSEE shall perform all toxicological, Phase I, Phase II or
other tests or studies necessary to obtain approval of a NDA and shall prepare,
prosecute and file any IND or NDA necessary to secure approval of all feasible
Licensed Products based on the Invention(s), Patent Rights or Technology in the
Licensed Field of Use. Upon notification from LICENSOR, as to any prospective
product, that LICENSOR has completed its research pursuant to paragraph 3.1,
LICENSEE shall promptly begin such studies and tests and diligently proceed with
them until approval has been obtained for all feasible Licensed Products.
LICENSEE shall thereafter use its best efforts to market, promote, manufacture
and sell any Licensed Products developed pursuant to this Agreement. If LICENSEE
determines that a potential Licensed product is not feasible, it

                                       3
<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

shall notify LICENSOR. Such notification shall relinquish any rights of LICENSEE
in said Licensed Product. Any dispute between the parties as to the feasibility
of a Licensed Product shall be resolved pursuant to Article 16 below.

      3.5 -- LICENSEE shall provide to LICENSOR, at least semi-annually, a
written report comprehensively describing its progress toward fulfillment of its
obligations pursuant to paragraph 3.4. If LICENSEE fails to make continuous and
reasonable progress toward the development of each feasible Licensed Product,
LICENSOR may notify LICENSEE of its dissatisfaction. In such event, LICENSOR and
LICENSEE shall negotiate in good faith in an attempt to resolve the basis for
such dissatisfaction. Should LICENSOR remain dissatisfied 30 days after such
notification, LICENSOR may, in its sole discretion, terminate this Agreement.

                                    4. GRANT

      4.1 -- LICENSOR hereby grants and LICENSEE hereby accepts a worldwide
license in the Licensed Field of Use to make, have made, use, and sell Licensed
Product(s).

      4.2 -- Said license, which includes the right to sublicense, shall be
Exclusive in the Licensed Field of Use.

                                  5. ROYALTIES

      5.1 -- (a) LICENSEE shall pay LICENSOR $[******] upon execution of this
Agreement;

      (b) LICENSEE shall pay to LICENSOR benchmark royalties relating to each
Licensed Product as follows:

            (1) $[*******] within 30 days after the IND approval;

            (2) $[*******] within 30 days after commencement of Phase I tests;

            (3) $[*******] within 30 days after commencement of Phase II tests;

            (4)$[*******] upon filing and an additional $[*******] upon approval
            of the NDA.

LICENSEE may investigate more than one Licensed Product through Phase II
tests, without paying more than one set of benchmark royalties. If LICENSEE
should choose to submit multiple NDAs or an NDA covering more than one Licensed
Product, then the benchmark royalties relating to additional Licensed Products
shall be reduced by [**]%. If, after obtaining approval of an NDA, LICENSEE
attempts to develop additional

                                       4
<PAGE>

Licensed Products, benchmark royalties relating to such products will by reduced
by 50%.

      5.2 -- In addition, LICENSEE shall pay LICENSOR earned royalties on Net
Sales by LICENSEE of [*****] percent ([*]%). LICENSEE shall pay to LICENSOR, as
royalties relating to any sublicense, the greater of (a) [*]% of Net Sales by
such sublicensee or (b) [*************************] percent ([****]%) of any
compensation LICENSEE receives from the sublicensee. If the Licensed Product is
solely for diagnostic use in the Licensed Field of Use, LICENSEE shall pay
LICENSOR earned royalties on Net Sales by LICENSEE or any sublicensee of [***]
percent ([*]%).

      5.3 -- The royalty on sales in currencies other than U.S. Dollars shall be
calculated using the appropriate foreign exchange rate for such currency quoted
by the Wall Street Journal, on the close of business on the last banking day of
each calendar quarter. Royalty payments to LICENSOR shall be in U.S. Dollars.

      5.4 -- In the event that the Patent Rights relating to a particular
Licensed Product are finally determined or adjudged by the Patent and Trademark
Office or a court of competent jurisdiction to be unpatentable or invalid, or
upon the expiration of the last patent covering such Licensed Product, LICENSEE
shall be entitled to a [**]% reduction in all royalties related to such Licensed
Product accruing pursuant to this Article 5, commencing on the effective date of
such determination, judgment or expiration.

                      6. REPORTS, PAYMENTS, AND ACCOUNTING

      6.1 -- Quarterly Royalty Payment and Report --LICENSEE shall make written
reports and royalty payments to LICENSOR within ninety (90) days after the end
of each calendar quarter following the first commercial sale. This report shall
state the number, description, and aggregate Net Sales of Licensed Produce(s)
during such completed calendar quarter, and resulting calculation of earned
royalty payment due LICENSOR for such completed calendar quarter. Concurrent
with the making of each such report, LICENSEE shall include payment due LICENSOR
of royalties for the calendar quarter covered by such report.

      6.2 -- Accounting -- LICENSEE agrees to keep records for a period of
two (2) years showing the manufacturing, sales, use, and other disposition of
products sold or otherwise disposed of under the license herein granted in
sufficient detail to enable the royalties payable hereunder by LICENSEE to be
determined, and further agrees to permit its books and records to be examined by
LICENSOR from time to time to the extent necessary to verify reports provided
for in Paragraph 5.1. Such examination is to be

                                       5
<PAGE>

made by LICENSOR, at its expense. If LICENSOR determines that LICENSEE has, for
any reason, failed to pay adequate royalties, LICENSEE shall immediately upon
notice thereof pay to LICENSOR any owed royalties plus interest at the rate of
eleven percent (11% per annum, compounded daily, calculated from the date upon
which such royalties should have been paid to the date of actual payment of
LICENSOR).

                                   7. WARRANTY

      LICENSOR represents and warrants that it has not granted the Patent Rights
or any rights in any Licensed Product(s) to any third party, except for United
States government rights which may have been required by law. LICENSOR also
represents and warrants that, to the best of LICENSOR'S knowledge, information
and belief, the Invention(s) are novel.

                                 8. INFRINGEMENT

      8.1 -- LICENSEE shall notify LICENSOR of any suspected infringement of the
Patent Rights by a third party.

      8.2 -- In the event that information becomes known to or is brought to the
attention of LICENSEE that others without license are unlawfully infringing upon
rights granted to LICENSEE pursuant to this Agreement, LICENSEE shall diligently
prosecute any infringer at LICENSEE's cost and expense. LICENSEE arid LICENSOR
acknowledge and agree that, although LICENSOR shall have the right at LICENSOR'S
option to prosecute infringers, LICENSOR is not desirous of being a party to any
such infringement suit. LICENSEE shall not join LICENSOR as a party-plaintiff to
any suit which LICENSEE may institute unless necessary for the maintenance of
said suit, and then only with the prior knowledge and written consent of
LICENSOR. In such event, LICENSOR shall not be chargeable for any costs or
expenses. LICENSOR shall execute all documents necessary for the prosecution of
any infringement suit brought by LICENSEE and provide other such support as
LICENSEE may require, all however at the expense, with respect to travel and the
like, of LICENSEE. LICENSEE is under no obligation to defend an action brought
by a third party alleging that the Patent Rights infringe an issued U.S. patent
or to defend a declaratory judgment action brought by a third party asserting
that the Patent Rights are invalid as anticipated by, or obvious over, prior
art.

                                       6
<PAGE>

      8.3 -- In the event that LICENSOR decides to institute suit, it shall
notify LICENSEE in writing. LICENSEE's failure to notify LICENSOR in writing,
within thirty (30) days after the date of notice, that it will join in enforcing
the patent pursuant to the provisions hereof, shall be deemed conclusively to be
LICENSEE's assignment to LICENSOR of all rights, causes of actions, and damages
resulting from any such alleged infringement, and LICENSOR shall be entitled to
retain the entire amount of any recovery or settlement. Furthermore, at its
option, LICENSOR may join LICENSEE as plaintiff.

      8.4 -- LICENSOR shall be entitled to the percentage of any recovery
obtained in any infringement suit brought by LICENSEE equal to the amount to
which LICENSOR would be entitled under the sublicensee royalty provision of this
Agreement had said recovery been paid to LICENSEE as sublicense royalties by the
defendant in said infringement suit. LICENSEE may deduct its reasonable costs
and attorneys fees incurred in prosecuting such suit, to the extent such costs
and fees are not otherwise recovered, prior to calculating the share owing to
LICENSOR pursuant to this provision.

      8.5 -- Should either LICENSOR or LICENSEE commence a suit under the
provisions of Paragraphs 8.2 or 8.3 and thereafter elect to abandon the same,
it shall give timely notice to the other party which may, if it so desires,
continue prosecution of such suit; provided, however, that the sharing of
expenses and any recovery in such suit shall be agreed upon between LICENSOR and
LICENSEE.

                       9. PROSECUTION OF LICENSED PATENTS

      9.1 -- LICENSEE agrees to accept liaison and financial responsibilities,
as hereinafter set forth, for the prosecution, by a patent lawyer in independent
practice, who shall be nominated by LICENSEE and approved by GEORGETOWN, of the
Licensed Applications. Said financial responsibilities shall not only include
the costs of prosecution but also the payment of maintenance fees, where
required, to maintain said patent applications and patents, if issued, in force
and effect for as long as possible. It is further agreed that the patent lawyer
selected by LICENSEE and approved by GEORGETOWN shall be required, if so desired
by GEORGETOWN, to keep a patent lawyer selected by GEORGETOWN informed of all
steps in the prosecution and maintenance of said Patent Rights. Written approval
will be required from GEORGETOWN to the patent lawyer selected by LICENSEE for
actions concerning this patent.

                                       7
<PAGE>

      9.2 -- Within two (2) weeks of notification to GEORGETOWN by LICENSEE of
the identity of the patent lawyer, GEORGETOWN will furnish to the patent lawyer
nominated in accordance with paragraph 9.1 above:

      (a) Complete file histories of all of the patent applications constituting
said Licensed Applications; and

      (b) An executed power of attorney or powers of attorney appointing such
patent lawyer as attorney of record in connection with all of said Licensed
Applications.

      9.3 -- GEORGETOWN shall have the right at any time, by notice in writing
and sent to LICENSEE by registered mail, to assume and continue at its own
expense, direction of the prosecution of any of said Licensed Applications. Upon
receipt by LICENSEE of any such notice from GEORGETOWN, LICENSEE and the patent
lawyer nominated in accordance herewith shall provide in two weeks from the time
of notice an executed power of attorney and all the file histories of the patent
applications constituting said Licensed Applications. Upon receipt of this
documentation, LICENSEE and the patent attorney nominated by LICENSEE shall be
relieved of all future responsibilities to prosecute the Licensed Applications
to which the notice is directed. If, for any reason, prosecution is to be
abandoned by LICENSEE, GEORGETOWN will be notified in sufficient time to assume
prosecution. LICENSEE shall bear all cost to maintain the patent prosecution
until such time that Georgetown can assume patent prosecution.

                                 10. TERMINATION

      10.1 -- LICENSOR may terminate this Agreement:

            (a) if LICENSEE is in default in payment of royalties or providing
of reports; or

            (b) if LICENSEE is in material breach of any provision hereof; and
LICENSEE fails to remedy any such default or breach within thirty (30) days
after written notice thereof by LICENSOR;

            (c) pursuant to paragraph 3.3 or 3.5; or

            (d) if LICENSEE is unable to provide adequate assurance of future
performance within sixty (60) days of written notice of LICENSOR's reasonable
belief that LICENSEE may not be able to perform its future obligations under
this Agreement, whether such belief is due to LICENSEE's financial circumstances
or other factors.

      10.2 -- Surviving any termination are:

            (a) LICENSEE's obligation to pay royalties accrued or accruable;

                                       8
<PAGE>

            (b) Any cause of action or claim of LICENSEE or LICENSOR, accrued or
to accrue, because of any breach or default by the other party; and

            (c) The provisions of Articles 6 and 8.

      10.3 -- In the event of termination of this Agreement for any reason, any
and all rights granted LICENSEE hereunder, including any rights granted by
LICENSEE to any sublicensee, shall cease and terminate, and all such rights
shall revert to LICENSOR. LICENSEE shall diligently thereafter return to
LICENSOR, or to LICENSOR's designated attorneys, any files or other documents in
its possession or in the possession of its attorneys, agents or sublicensees,
relating to pending or issued Licensed Patent(s), and shall execute any and all
documents necessary to return control of said Licensed Patent(s) until such time
as control has properly been transferred to LICENSOR. Further, LICENSEE shall
immediately return to LICENSOR all research data, biological and other material
(including but not limited to licensed cell lines), prototypes, process
information, clinical data, and the like of LICENSOR in its possession or in the
possession of its sublicensees.

                               11. CONFIDENTIALITY

      11.1 -- LICENSEE agrees not to disclose or transfer any technical reports,
data and information provided to the LICENSEE by LICENSOR, including the
contents of Licensed Applications to any person other than its employees and
consultants, without prior written approval of LICENSOR. Should LICENSEE wish to
disclose any such information to a third party, it shall provide LICENSOR with
the identity of such party, the purpose of the disclosure, the text of the
proposed disclosure and a proposed confidentiality agreement to be executed by
the third party prior to disclosure of the confidential information. LICENSOR
shall respond within ten working days of any such request for consent to
disclosure, which consent will not be unreasonably withheld.

      11.2 -- LICENSEE shall not utilize any Invention, Patent Rights or
Technology in connection with any research or product development in which it
may engage except pursuant to this Agreement. Upon request, LICENSEE shall
permit LICENSOR access to its records and facilities sufficient to confirm
whether such use is occurring.

      11.3 -- LICENSEE shall not use LICENSOR's name or refer to LICENSOR in any
promotion, marketing or solicitations without providing LICENSOR a copy of any
such proposed use or reference and obtaining LICENSOR's prior approval in
writing.

      11.4 -- LICENSOR shall have the right to distribute information relating
to the Invention(s) to (i) academic investigators at not-for-profit institutions
for non-commercial

                                       9
<PAGE>

research purposes, and (ii) third parties for the purpose of obtaining chemical,
physical, or biological analysis or characterization of any information
necessary for furtherance of LICENSOR's academic research. Nothing in this
Paragraph shall limit the right of LICENSOR to disclose any information which,
through no fault of LICENSOR, becomes generally available to the public.

      11.5 -- Nothing in this Agreement shall limit in any way LICENSOR's
 ability to undertake (i) the filing of any report required by any public
authority, or (ii) the non-public disclosure and discussion of information
between investigators and their academic colleagues.

                              12. PUBLICATION RIGHTS

      12.1 -- LICENSOR shall have the right to publish, disclose and disseminate
("Right to Publish") in whole or in part, any data and information related to
the Invention(s). LICENSEE agrees that it shall not under any circumstances use
the name or names of the LICENSOR or of its employees or contractors, or any
adaptation thereof, (i) in any advertising, promotional, or sales literature,
securities prospectus, press release or other publicity relating to any
invention, discovery or other commercially exploitable product or process, (ii)
on any invention, discovery or other commercially exploitable product or
process, or (iii) generally on any matter arising out of this Agreement, without
prior written consent of LICENSOR.

                                 13. ASSIGNMENT

      LICENSEE may not assign any right or delegate any obligation under this
Agreement without the prior written consent of LICENSOR. Consent of the LICENSOR
shall not be unreasonably withheld with respect to publicly traded companies.
Any change in the ownership interests in LICENSEE that exceeds 50% within a
one-year period shall be deemed an assignment.

                               14. INDEMNIFICATION

      14.1 -- LICENSEE agrees that during the term of this Agreement and
thereafter, it will indemnify, defend and hold GEORGETOWN, its trustees,
officers, employees and affiliates, harmless against all claims and expenses,
including legal expenses and attorneys' fees, arising out of the death of or
injury to any person or persons, or out of any damage to property, and against
any other claim, proceeding, demand, expense and

                                       10
<PAGE>

liability of any kind whatsoever resulting from the production, manufacture,
sales, use, consumption or advertisement of Licensed Products by LICENSEE.

                                   15. NOTICES

      All notices under this Agreement shall be deemed to have been fully given
when done in writing and deposited in the United States mail, registered or
certified, and addressed as follows:

To LICENSOR:                                            To LICENSEE:
GEORGETOWN UNIVERSITY                                   ZEBRA PHARMACEUTICALS
Director                                                Attn: David Elmaleh
Office of Technology Transfer                           38 Hartman Road
2115 Wisconsin Avenue, N.W.                             Newton, MA 02159
Suite 108
Washington, D.C. 20007

      Either party may change its address upon notice to the other party as
provided herein.

                             16. DISPUTE RESOLUTION

      Should the parties hereafter have any dispute as to their obligations
pursuant to this Agreement, they shall first attempt to resolve such dispute
among themselves. If such efforts are not successful, the exclusive method for
resolving such a dispute shall be arbitration as described herein.

      Either party may elect to submit the issue to arbitration by giving
written notice to the other party and naming an arbitrator. The other party will
then have 30 days to select its own arbitrator. Once both arbitrators have been
selected they shall meet within 30 days of the appointment of the second
arbitrator and select a third arbitrator mutually agreeable to them.

      If the dispute relates to the scope of the Patent Rights, Field of Use or
Technology or the feasibility of a Licensed Product, then all arbitrators
selected pursuant to this provision shall have adequate scientific
qualifications, including an advanced degree in a field related to biochemistry
and significant research experience.

                                       11
<PAGE>

      Once the patent of arbitrators have been chosen, they shall conduct an
arbitration on the disputed issue or issues in accordance with the Commercial
Arbitration Rules of the American Arbitration Association. The third arbitrator
shall serve as the presiding arbitrator, although, in the event of dispute among
the arbitrators, the majority decision of the arbitration panel shall be
binding. The decision of the arbitrators shall be final and either party may
apply to a court located in the District of Columbia to enter judgment based on
the arbitrator's decision. All costs of the arbitrators and the arbitration,
other than the respective parties' attorneys' fees and costs, shall be borne
equally by the parties.

                                   17. WAIVER

      None of the terms, covenants, and conditions of this Agreement can be
waived except by the written consent of the party waiving compliance.

                               18. APPLICABLE LAW

      This Agreement shall be construed, interpreted, and applied in accordance
with the laws of the District of Columbia and applicable federal laws.

                              19. ENTIRE AGREEMENT

      This writing constitutes the entire agreement of the parties and there are
no promises, understandings, or agreements of any kind pertaining to this
agreement other than those written in this agreement.

                         [Signatures follow on page 13]

                                       12
<PAGE>

   IN WITNESS WHEREOF the parties thereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

Date  12-5-97                                  Date 12/18/97

For GEORGETOWN UNIVERSITY                      For XEBRA PHARMACEUTICALS

By : /s/ Gregory B. Raymond                    By : /s/ David Elmaleh
     ----------------------                         -----------------------
     Gregory B. Raymond                              David Elmaleh, Ph.D.
     Acting Chief Operating Officer                 President

/s/ Arthur Raines
--------------------------------------
Arthur Raines, Ph.D.
Acting Associate Dean for Research Operations

/s/ Wm. Jack Hartman
--------------------------------------
Wm. Jack Hartman
Director of Research Grants and Contracts

/s/ Carol Tracy Carr
--------------------------------------
Carol Tracy Carr, Esq.
Director, Office of Technology Transfer

                                       13
<PAGE>

                    STATEMENT OF WORK CONCERNING THE RESEARCH
                 CONTRACT BETWEEN GU AND ZEBRA PHARMACEUTICALS.

              PREPARED BY PROFESSOR KOZIKOWSKI, GU MEDICAL CENTER

      Immediate therapies are needed for the treatment of cocaine abuse
worldwide. In this direction, we have recently identified a piperidine-based
analog of cocaine (specifically, the trans isomer of 1-methyl
-4-(4-chlorophenyl)piperidine-3-carboxylic acid methyl ester) that binds to the
cocaine recognition site with comparable affinity to cocaine; additionally, this
compound acts as an inhibitor of dopamine uptake. In spite of the compound's
potency, it has been observed that in discrimination studies in rats, the
compound exhibits only weak cocaine- and amphetamine-like effects. Unlike
cocaine, this compound has weak motor stimulant effects and is not
self-administered by rats. These results appear to be promising from the
standpoint of discovering a possible medication for drug abuse treatment. In
order to properly follow up on these encouraging preliminary results, it is our
plan to conduct further chemical analog synthesis, in vitro pharmacological
studies, and in vivo animal experiments on the 4-phenylpiperidine analogs with
the objective to improve upon the biological profile of this compound.

      Within the context of the research contract with Zebra Pharmaceuticals, it
is our intention to pursue the following specific aim:

      To conduct additional structure-activity relationship studies in this
piperidine series in order to establish that we are advancing the best compound
as a possible medication. These studies would include preparation of the lead
structure in larger amounts in optically pure form, and the design and synthesis
of related analogs embodying the following structural changes: a) modification
of the nature and position of the substituent borne by the

<PAGE>
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

Phenyl ring; b) replacement of the N-methyl group by other alkyl groups and
sulfonyl groups, as well as isosteric replacement of NMe by CH(2) and O; c)
replacement of the ester group by alkyl and alkenyl groups.

      A budget that reflects how the initial one year budget of $[******] will
be spent is attached.
<PAGE>
             AMENDMENT TO RESEARCH AGREEMENT AND EXCLUSIVE LICENSE

                             Dated October 27, 2005

Between Molecular Insight Pharmaceuticals, Inc. (formerly designated in the
above referenced Agreement as Zebra Pharmaceuticals) and Georgetown University.

     This Amendment serves to modify the Agreement entered into December 29,
1997 for Patent Rights and Technology related to US Patent Application Serial
No. 60/042,775 (filed April 7, 1997) entitled "Analogs of Cocaine", as well as
any foreign applications corresponding thereto, and any divisions,
continuations, or any reexaminations thereof, and will be enforceable on the
date of the last signature of this Second Amendment.

     Molecular Insight Pharmaceuticals, Inc. and Georgetown University agree
that the following provisions in the above referenced agreement shall be
modified as follows:

                                    PREAMBLE

The Agreement preamble formerly reciting:

     Effective as of December 29, 1997, GEORGETOWN UNIVERSITY, a not-for-profit
corporation of the District of Columbia, having a principal address at 37th & O
Streets, N.W., Washington, D.C. 20057 ("LICENSOR") and ZEBRA PHARMACEUTICALS, a
Massachusetts corporation, having a principal place of business at 160 Second
St., Cambridge, Massachusetts 02142 ("LICENSEE"), agrees as follows:

Shall be replaced by:

     Effective as of December 29, 1997, GEORGETOWN UNIVERSITY, a not-for-profit
corporation of the District of Columbia, having a principal address at 37th & O
Streets, N.W., Washington, D.C. 20057 ("LICENSOR") and MOLECULAR INSIGHT
PHARMACEUTICALS, a Massachusetts corporation, having a principal place of
business at 160 Second St., Cambridge, Massachusetts 02142 ("LICENSEE"), agree
as follows:

                                 2. DEFINITIONS

Section 2.1 formerly reciting:

     2.1 "Patent Rights" refers to LICENSOR's rights arising from U.S.
Provisional Patent Applications Serial No. 60/042,775, filed April 7, 1997
entitled "Analogs of Cocaine", and naming as inventors Alan P. Kozikowski, and
Gian Luca Araldi, including the information contained in said application with
respect to the Invention(s) any foreign patent applications corresponding
thereto, any United States divisions, continuations, reissues, or
reexaminations thereof, and any patent(s) issued or granted therefrom. Such
patent application(s) are the "Licensed Application(s)" and any resulting
patents are the "Licensed Patent(s)."

<PAGE>
Shall be replaced by:

     2.1 "Patent Rights" refers to LICENSOR's rights arising from U.S.
Provisional Patent Application Serial No. 60/042,775, filed April 7, 1997
entitled "Analogs of Cocaine", including the information contained in said
application with respect to the Invention(s) any foreign patent applications
corresponding thereto, any United States divisions, continuations, continuations
in-part to the extent the claims are directed to subject matter specifically
described in PCT/US98/07081, reissues, or reexaminations thereof, and any
patent(s) issued or granted therefrom, specifically, 6,180,648, 6,472,422 and
6,806,281, all to the extent owned or controlled by Georgetown. Such patent
application(s) are the "Licensed Application(s)" and any resulting patents are
the "Licensed Patents(s)."

In witness thereof, the parties have executed this Amendment on the dates
indicated.

MOLECULAR INSIGHT                       GEORGETOWN UNIVERSITY
PHARMACEUTICALS, INC.

By:                                     By:    /s/ Martin A. Mullins
    --------------------------              --------------------------
Name:  John W. Babich                   Name:  Martin Mullins
Title: President and CSO                Title: Vice President
                                               Office of Technology Transfer

Date:                                   Date:     11/1/05
     -------------------------               -------------------------

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]